

## Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross® has confirmed that the shortage for Apo-Gliclazide MR 30 mg Sustained-Release Tablet (DIN 02297795) and Taro-Gliclazide MR 30 mg Sustained-Release Tablet (DIN 02463571) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **May 23, 2025**. The following grouping was removed from the Critical Supply Product List on **April 23, 2025**.

### GLICLAZIDE

#### 30 MG SUSTAINED-RELEASE TABLET

00002297795	APO-GLICLAZIDE MR	APX	\$ 0.0931
00002524856	GLICLAZIDE MR	SNS	\$ 0.0931
00002429764	JAMP GLICLAZIDE-MR	JPC	\$ 0.0931
00002423286	MINT-GLICLAZIDE MR	MPI	\$ 0.0931
00002438658	MYLAN-GLICLAZIDE MR	MYP	\$ 0.0931
00002463571	TARO-GLICLAZIDE MR	SPG	\$ 0.0931
00002242987	DIAMICRON MR	SEV	\$ 0.1628

Alberta Blue Cross has confirmed that the shortage for Teva-Liothyronine 5 mcg Tablet (DIN 02494337) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **May 26, 2025**. The following grouping was removed from the Critical Supply Product List on **April 25, 2025**.

### LIOTHYRONINE SODIUM

#### 5 MCG TABLET

00002494337	TEVA-LIOTHYRONINE	TEV	\$ 1.1587
00001919458	CYTOMEL	PFI	\$ 1.4133

continued next page

continued from previous page

Alberta Blue Cross has confirmed that the shortage for Jamp Pyridostigmine Bromide 60 mg Tablet (DIN 02508362) and Riva-Pyridostigmine 60 mg Tablet (DIN 02495643) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **May 29, 2025**. The following grouping was removed from the Critical Supply Product List on **April 29, 2025**.

## PYRIDOSTIGMINE BROMIDE

### 60 MG TABLET

<b>00002508362</b>	<b>JAMP PYRIDOSTIGMINE BROMIDE</b>	<b>JPC</b>	<b>\$ 0.2673</b>
<b>00002495643</b>	<b>RIVA-PYRIDOSTIGMINE</b>	<b>RIV</b>	<b>\$ 0.2673</b>
00000869961	MESTINON	VCL	\$ 0.5565

Alberta Blue Cross has confirmed that the shortage for Clarus 10 mg Capsule (DIN 02257955) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **June 2, 2025**. The following grouping was removed from the Critical Supply Product List on **May 1, 2025**.

## ISOTRETINOIN

### 10 MG CAPSULE

<b>00002257955</b>	<b>CLARUS</b>	<b>MYP</b>	<b>\$ 0.9313</b>
00000582344	ACCUTANE	HLR	\$ 0.9776

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)  
403-294-4041 (Calgary and area)  
1-800-361-9632 (toll free)  
FAX 780-498-8406 (Edmonton and area)  
FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct-bill drug claims.

Visit [ab.bluecross.ca/providers/pharmacy-home.php](http://ab.bluecross.ca/providers/pharmacy-home.php)

